Efficacy of continuous infusion of vancomycin for the outpatient treatment of methicillin-resistant staphylococcus aureus infections

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 12, 2012, Pages 2970-2973

  Verrall, Ayesha J ^a   Llorin, Ryan ^b   Tam, Vincent H ^a,c   Lye, David C ^b   Sulaiman, Zuraidah ^d   Zhong, Lihua ^b   Archuleta, Sophia ^a   Fisher, Dale A ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b TAN TOCK SENG HOSPITAL   (Singapore)

^c UNIVERSITY OF HOUSTON   (United States)

^d NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

Administration; Intermittent infusion; OPAT

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; COTRIMOXAZOLE; RIFAMPICIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; COHORT ANALYSIS; COMORBIDITY; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; OUTPATIENT DEPARTMENT; PROSTHESIS; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; COHORT STUDIES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; TREATMENT FAILURE; VANCOMYCIN; YOUNG ADULT;

EID: 84869389122     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks328     Document Type: Article

References (9)

1. Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52: e18-55.
2. Wysocki M, Delatour F, Faurisson F et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001; 45: 2460-7.
3. Cataldo MA, Tacconelli E, Grilli E et al. Vancomycin way of administration: where is the evidence? Clin Infect Dis 2011; 53: 308-10.
4. Chapman ANL, Dixon S, Andrews D et al. Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective. Antimicrob Agents Chemother 2009; 64: 1316-24.
5. Cataldo MA, Tacconelli E, Pea F et al. Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother 2012; 67: 17-24.
6. Ebert S. In vivo cidal activity and PK parameters for vancomycin against MSSA and MRSA. In: Abstracts of the Twenty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, New York, NY, 1987. Abstract 439, p. 173. American Society for Microbiology, Washington, DC, USA.
7. Moise-Broder PA, Forrest A, Birmingham MC et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet 2004; 43: 925-42.
8. Nicasio AM, Bulitta JB, Lodise TP et al. Evaluation of once-daily vancomycin against methicillin-resistant Staphylococcus aureus in a hollow-fiber infection model. Antimicrob Agents Chemother 2012; 56: 682-6.
9. Ingram PA, Lye DC, Fisher DA et al. Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy. Int J Antimicrob Agents 2009; 34: 570-4.